Bright Minds Biosciences Inc. (CSE: DRUG)
Canada
· Delayed Price · Currency is CAD | Market Cap | 250.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.58M |
| Shares Out | 4.46M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,529 |
| Open | 59.62 |
| Previous Close | 60.21 |
| Day's Range | 58.00 - 60.00 |
| 52-Week Range | 1.29 - 108.00 |
| Beta | 1.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 27, 2024 |
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with ... [Read more]
Financial Performance
Financial StatementsNews
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of ...
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most...
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demons...
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares
What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ: DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly N...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing no...
Monster insider trading alert for this penny stock that rallied $3,700% in a week
This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed … Continue reading The post Monster insider trading al...
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving ... Full story available on Benzinga.com
Bright Minds rebounds after $35M private placement
Bright Minds Biosciences (DRUG) stock surged by ~48% in premarket trading after the company announced a $35M private placement mainly for R&D. Read more here.
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Perceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences Inc
Perceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences Inc
Bright Minds rally ends as psychedelic stocks extend volatility
Bright Minds Biosciences (DRUG) stock fell 29% following over 15-fold ris in the previous session as psychedelic drug developers experienced volatility. Read more here.
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Bioscience...
Why did this penny stock skyrocket 1,500% in a day
When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a … Continue reading The post Why did this penny stock skyrocke...
Biotech stock tumbles after unexplained 1,446% gain
Bright Minds Biosciences, which until this week had a lightly traded stock that traded at just over $1, tumbled in premarket trade on Wednesday following a meteoric rise.
Bright Minds is Unaware of Any Material Changes
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm ...
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnerin...
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on Septem...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. ...
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
Bright Minds Biosciences Inc . (NASDAQ: DRUG) has released its Management’s Discussion and Analysis (MD&A) for the third quarter ending June 30, 2024 , showcasing a substantial reduction in net losse...
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-cons...
Bright Minds Announces Effective Date of Share Consolidation
VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing...